|
Volumn 43, Issue 6, 2011, Pages 2450-2452
|
Controversies about induction therapy
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALEMTUZUMAB;
BASILIXIMAB;
BELATACEPT;
CALCINEURIN INHIBITOR;
DACLIZUMAB;
IMMUNOSUPPRESSIVE AGENT;
INTERLEUKIN 2 RECEPTOR ANTIBODY;
RAPAMYCIN;
THYMOCYTE ANTIBODY;
ACUTE GRAFT REJECTION;
ARTICLE;
CORTICOSTEROID THERAPY;
CYTOMEGALOVIRUS INFECTION;
DELAYED GRAFT FUNCTION;
DRUG BINDING;
DRUG MEGADOSE;
GRAFT RECIPIENT;
GRAFT SURVIVAL;
HEPATITIS C;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
INFECTION COMPLICATION;
KIDNEY FAILURE;
KIDNEY GRAFT REJECTION;
LIVER GRAFT REJECTION;
LIVER TRANSPLANTATION;
LOW DRUG DOSE;
LYMPHOPROLIFERATIVE DISEASE;
MAINTENANCE THERAPY;
NEPHROTOXICITY;
PRIORITY JOURNAL;
REPERFUSION INJURY;
VIRUS LOAD;
DELAYED GRAFT FUNCTION;
GRAFT REJECTION;
GRAFT SURVIVAL;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
ORGAN TRANSPLANTATION;
TREATMENT OUTCOME;
|
EID: 80051678360
PISSN: 00411345
EISSN: 18732623
Source Type: Journal
DOI: 10.1016/j.transproceed.2011.06.021 Document Type: Article |
Times cited : (5)
|
References (28)
|